Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganagliflozin proline tablets in type 2 diabetes mellitus or prediabetes with carotid plaque
ChiCTR2600132711Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ganagliflozin in type 2 diabetes mellitus (T2DM) and prediabetes (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Rate of glycemic remission at Week 32. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ganagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on ChiCTR2600132711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132711.